Ecological photodynamic therapy: New trend to disrupt the intricate networks within tumor ecosystem

Vittar, Natalia Belén Rumie; Lamberti, María Julia; Pansa, María Florencia; Vera, Renzo E.; Rodríguez, Matías Exequiel; Cogno, Ingrid Sol; Sanabria, Laura Natalia Milla; Rivarola, Viviana

doi:10.1016/j.bbcan.2012.10.004

Cited by 17 publications

(10 citation statements)

References 137 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…After administration of the photosensitizer agent (PS), tumor loci are irradiated with a PS-exciting light of specific wavelength. None of these are independently toxic, but together produce a photochemical reaction, turning molecular oxygen into reactive oxygen species (ROS), which act directly on tumor cells or indirectly by damaging tumor-associated vasculature (18–22).…”

Section: Introductionmentioning

confidence: 99%

Photodynamic Modulation of Type 1 Interferon Pathway on Melanoma Cells Promotes Dendritic Cell Activation

et al. 2019

Self Cite

View full text Add to dashboard Cite

The immune response against cancer generated by type-I-interferons (IFN-1) has recently been described. Exogenous and endogenous IFN-α/β have an important role in immune surveillance and control of tumor development. In addition, IFN-1s have recently emerged as novel DAMPs for the consecutive events connecting innate and adaptive immunity, and they also have been postulated as an essential requirement for induction of immunogenic cell death (ICD). In this context, photodynamic therapy (PDT) has been previously linked to the ICD. PDT consists in the administration of a photosensitizer (PS) and its activation by irradiation of the affected area with visible light producing excitation of the PS. This leads to the local generation of harmful reactive oxygen species (ROS) with limited or no systemic defects. In the current work, Me-ALA inducing PpIX (endogenous PS) was administrated to B16-OVA melanoma cells. PpIX preferentially localized in the endoplasmic reticulum (ER). Subsequent PpIX activation with visible light significantly induced oxidative ER-stress mediated-apoptotic cell death. Under these conditions, the present study was the first to report the in vitro upregulation of IFN-1 expression in response to photodynamic treatment in melanoma. This IFN-α/β transcripts upregulation was concurrent with IRF-3 phosphorylation at levels that efficiently activated STAT1 and increased ligand receptor (cGAS) and ISG (CXCL10, MX1, ISG15) expression. The IFN-1 pathway has been identified as a critical molecular pathway for the antitumor host immune response, more specifically for the dendritic cells (DCs) functions. In this sense, PDT-treated melanoma cells induced IFN-1-dependent phenotypic maturation of monocyte-derived dendritic cells (DCs) by enhancing co-stimulatory signals (CD80, MHC-II) and tumor-directed chemotaxis. Collectively, our findings showed a new effect of PDT-treated cancer cells by modulating the IFN-1 pathway and its impact on the activation of DCs, emphasizing the potential relevance of PDT in adoptive immunotherapy protocols.

show abstract

Section: Introductionmentioning

confidence: 99%

Photodynamic Modulation of Type 1 Interferon Pathway on Melanoma Cells Promotes Dendritic Cell Activation

et al. 2019

Self Cite

View full text Add to dashboard Cite

show abstract

“…On the other hand, ECs have several beneficial characteristics when they are selected as PDT targets [5]. We were able to establish that they are more sensitive to PDT than tumor cells; however, despite these promising results, our data indicated that there is a tendency for ECs to proliferate when they have been exposed to lethal PDT and then tumor stimulated.…”

Section: Discussionmentioning

confidence: 66%

Photodynamic therapy potentiates the paracrine endothelial stimulation by colorectal cancer

Lamberti¹,

Pansa²,

Vera³

et al. 2014

Laser Phys.

Self Cite

View full text Add to dashboard Cite

show abstract

“…PDT is clinically used in the treatment of various superficial cancer types, however, with limited success [146, 147]. The major limitation of PDT is the secondary induction of angiogenic pathways in response to tissue hypoxia and tissue damage, resulting from blood vessel closure, consequently leading to enhanced tumor growth after treatment [148, 149]. Therefore, a promising strategy to overcome these secondary effects is through the combination of PDT with anti-angiogenic drugs [150–152].…”

Section: Combination Of Mirna Therapy and Photodynamic Therapymentioning

confidence: 99%

miRNAs: micro-managers of anticancer combination therapies

et al. 2017

View full text Add to dashboard Cite

Angiogenesis is one of the hallmarks of cancer progression and as such has been considered a target of therapeutic interest. However, single targeted agents have not fully lived up to the initial promise of anti-angiogenic therapy. Therefore, it has been suggested that combining therapies and agents will be the way forward in the oncology field. In recent years, microRNAs (miRNAs) have received considerable attention as drivers of tumor development and progression, either acting as tumor suppressors or as oncogenes (so-called oncomiRs), as well as in the process of tumor angiogenesis (angiomiRs). Not only from a functional, but also from a therapeutic view, miRNAs are attractive tools. Thus far, several mimics and antagonists of miRNAs have entered clinical development. Here, we review the provenance and promise of miRNAs as targets as well as therapeutics to contribute to anti-angiogenesis-based (combination) treatment of cancer.

show abstract

Ecological photodynamic therapy: New trend to disrupt the intricate networks within tumor ecosystem

Cited by 17 publications

References 137 publications

Photodynamic Modulation of Type 1 Interferon Pathway on Melanoma Cells Promotes Dendritic Cell Activation

Photodynamic Modulation of Type 1 Interferon Pathway on Melanoma Cells Promotes Dendritic Cell Activation

Photodynamic therapy potentiates the paracrine endothelial stimulation by colorectal cancer

miRNAs: micro-managers of anticancer combination therapies

Contact Info

Product

Resources

About